"Graft vs Tumor Effect" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Immunological rejection of tumor tissue/cells following bone marrow transplantation.
| Descriptor ID |
D020350
|
| MeSH Number(s) |
G12.875.402.320
|
| Concept/Terms |
Graft vs Tumor Effect- Graft vs Tumor Effect
- Graft vs Neoplasm Effect
- Graft-vs-Tumor Response
- Graft vs Tumor Response
- Graft-vs-Tumor Responses
- Response, Graft-vs-Tumor
- Responses, Graft-vs-Tumor
- Graft-vs-Neoplasm Response
- Graft vs Neoplasm Response
- Graft-vs-Neoplasm Responses
- Response, Graft-vs-Neoplasm
- Responses, Graft-vs-Neoplasm
- Graft-vs-Neoplasm Effect
- Effect, Graft-vs-Neoplasm
- Effects, Graft-vs-Neoplasm
- Graft-vs-Neoplasm Effects
- Graft-vs-Tumor Effect
- Effect, Graft-vs-Tumor
- Effects, Graft-vs-Tumor
- Graft-vs-Tumor Effects
|
Below are MeSH descriptors whose meaning is more general than "Graft vs Tumor Effect".
Below are MeSH descriptors whose meaning is more specific than "Graft vs Tumor Effect".
This graph shows the total number of publications written about "Graft vs Tumor Effect" by people in this website by year, and whether "Graft vs Tumor Effect" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 2 | 2 |
| 1999 | 6 | 0 | 6 |
| 2000 | 1 | 1 | 2 |
| 2001 | 0 | 3 | 3 |
| 2002 | 1 | 1 | 2 |
| 2003 | 0 | 4 | 4 |
| 2004 | 3 | 1 | 4 |
| 2005 | 1 | 0 | 1 |
| 2006 | 0 | 2 | 2 |
| 2007 | 2 | 3 | 5 |
| 2008 | 1 | 4 | 5 |
| 2010 | 1 | 2 | 3 |
| 2011 | 0 | 3 | 3 |
| 2012 | 0 | 2 | 2 |
| 2015 | 0 | 1 | 1 |
| 2017 | 0 | 2 | 2 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Graft vs Tumor Effect" by people in Profiles.
-
Invariant natural killer T-cell subsets have diverse graft-versus-host-disease-preventing and antitumor effects. Blood. 2021 09 09; 138(10):858-870.
-
Systemic ?-Adrenergic Receptor Activation Augments the ex vivo Expansion and Anti-Tumor Activity of V?9Vd2 T-Cells. Front Immunol. 2019; 10:3082.
-
NK cell therapy after hematopoietic stem cell transplantation: can we improve anti-tumor effect? Int J Hematol. 2018 Feb; 107(2):151-156.
-
The recipient CCR5 variation predicts survival outcomes after bone marrow transplantation. Transpl Immunol. 2017 06; 42:34-39.
-
Allogeneic Hematopoietic Cell Transplantation for Myeloma: When and in Whom Does It Work. Curr Hematol Malig Rep. 2017 04; 12(2):126-135.
-
Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2015 Jun; 21(6):971-83.
-
Will post-transplantation cell therapies for pediatric patients become standard of care? Biol Blood Marrow Transplant. 2015 Mar; 21(3):402-11.
-
Nonmyeloablative allogeneic stem cell transplantation for non-hodgkin lymphoma. Cancer J. 2012 Sep-Oct; 18(5):457-62.
-
Durable responses after donor lymphocyte infusion for patients with residual multiple myeloma following non-myeloablative allogeneic stem cell transplant. Leuk Lymphoma. 2012 Aug; 53(8):1525-9.
-
Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol. 2011 Dec; 12(13):1195-203.